Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Vacuna contra la caries dental

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOPT20150909001
Publicado:
07/12/2015
Caducidad:
07/12/2016
Resumen:
Una universidad portuguesa ha desarrollado una vacuna contra la caries dental capaz de inducir anticuerpos de inmunoglobulina A secretora (sIgA) en saliva dirigidos a dos cepas bacterianas que son los principales agentes causantes de la caries dental. La inmunoglobulina A secretora constituye el principal mecanismo de defensa inmune específico en la saliva y desempeña una función importante en la homeostasis de la microbiota oral. Estos anticuerpos controlan la microbiota oral reduciendo la adherencia de las bacterias a la mucosa oral y a los dientes. Se buscan socios con el fin de establecer acuerdos de licencia o comercialización con asistencia técnica.

Details

Tittle:
Vaccine against dental caries
Summary:
A Portuguese University has developed a vaccine against dental caries capable of induction of secretory Immunoglobulin A (sIgA) antibodies in saliva targeting two strains of bacteria implicated as the primary causative agents for dental caries. It is seeking partners for licensing or a commercialization agreement with technical assistance.
Description:
Dental caries are considered one of the most common diseases and the development of a vaccine against dental caries has been exhaustively researched for several years.

Secretory Immunoglobulin A (IgA) constitutes the main specific immune defense mechanism in saliva and may play an important role in the homeostasis of the oral microbiota.

These antibodies may control the oral microbiota by reducing the adherence of bacteria to the oral mucosa and teeth. It is thought that protection against bacterial etiologic agents of caries and periodontal diseases could be conferred by the induction of sIgA antibodies via the stimulation of the oral mucosal immune system.

The number of authorized vaccines used to confer immunity in humans represents a very small percentage of all the pathogenic microorganisms known worldwide. There is not yet available any effective vaccine against fungi, protozoa or helminths.

This vaccine prevents and treats dental infection when it occurs. The vaccination protocols are preventive and therapeutic, that is, immunization can be achieved before or after oral cavity infection with bacterium. Mammals can be immunized through different routes, such as intranasal, oral and subcutaneous.

This vaccine can be incorporated into a paste or mouthwash for the prevention of dental caries, this would considerably reduce FDA approval.

The research group is seeking partners for licensing or a commercialization agreement with technical assistance.

The partner sought should be an industrial, pharmaceutical, cosmetics or tooth care organisation with expertise in immunology and pharma products development.
It is expected to carry out further development of the vaccine including pre-clinical tests, clinical tests and commercialization.
Advantages and Innovations:
This vaccine simultaneously prevents and treats dental infection when it occurs as immunization through the vaccine can be achieved before or after oral cavity infection with bacterium. Immunization can be achieved in mammals through several routes, such as intranasal, oral and subcutaneous.
Stage of Development:
Under development/lab tested
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Patent granted in Portugal and the USA.

Partner sought

Type and Role of Partner Sought:
The research group is seeking business partners for technology transfer (e.g. licensing or commercial agreement with technical assistance).
The partner sought should be an industrial, pharmaceutical, cosmetics or tooth care organisation with expertise in immunology and pharma products development. It should be able to carry out further development of the vaccine including pre-clinical tests, clinical tests and commercialization.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French
Portuguese
Spanish

Keywords

Technology Keywords:
06001004 Cirugía dental / odontología, estomatología
06001006 Vacunas humanas